Myotonic dystrophy: reproductive cancer risk factors in women

  • Higgs C & al.
  • Front Neurol
  • 1 Jan 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • This study found no significant reproductive cancer factor differences between female myotonic dystrophy type 1 (DM1) and type 2 (DM2) individuals, except for a possibility of a higher frequency of hysterectomy and hormone therapy (HT) use in DM2 patients.

Why this matters

  • Findings warrant larger studies to evaluate the possible link between reproductive cancer risk factors and the risk of tumors in women.

Study design

  • This study included 286 women, clinically confirmed as having DM and self-enrolled in the UK DM Registry (n=124: DM1=120, DM2=4) and the US National Registry of DM (n=162: DM1=122, DM2=40
  • Differences in reproductive cancer risk factors by DM subtype assessed using questionnaires.       
  • Funding: Intramural Research Program of the Division of Cancer Epidemiology and Genetics, and others.

Key results

  • DM2 patients were older than DM1 patients in both countries (mean age, US: 59.8 vs 51.2 years, P=.0001; UK: 52.2 vs 46.2 years, P=.37).
  • No statistically significant differences were observed between DM1 and DM2 regarding menstrual history or fertility-related factors.
  • Women with DM2 vs those with DM1 were more likely to have used menopausal HT (52.3% vs 22.1%; P<.0001 and had a hysterectomy vs p>
  • The frequency of self-reported reproductive organ tumours was not significantly different comparing DM1 with DM2 (P=.28).
  • Women with DM2 vs those with DM1 had a lower risk for malignant tumours (OR, 0.72; P=.69).

Limitations

  • Self-reported data.
  • Results may not be generalisable to the entire DM population.